Ceftriaxone therapy for serious bacterial infections

D. S. Lockman, R. C. Trincher, J. P. Rissing

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Ceftriaxone is a new semisynthetic cephalosporin with a very long serum half-life and broad coverage against Enterobacteriaceae and Pseudomonas aeruginosa. Clinical and microbiological efficacies were evaluated in 51 infections occurring in 46 patients: 20 pneumonias, 19 urinary tract infections, seven soft-tissue infections, two septic arthritis infections, two primary bacteremias and one otitis media. The usual dose of ceftriaxone was one gram every 12 hours. Improvement of cure occurred in 92% of infections; microbiological cure occurred in 93% of infections. A mild rise in liver function tests occurred in 14% of the 51 infections but was not thought clinically significant.

Original languageEnglish (US)
Pages (from-to)574-581
Number of pages8
JournalCurrent Therapeutic Research - Clinical and Experimental
Issue number3
StatePublished - 1984

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Ceftriaxone therapy for serious bacterial infections'. Together they form a unique fingerprint.

Cite this